Top headlines: Modi to visit Serum Institute, farmers' protests, more

Union Agriculture Minister Narendra Singh Tomar said the government is ready to talk with farmers on December 3, and resolve differences

Modi to visit Serum Institute on Saturday

Interim data from the Indian arm of Oxford-AstraZeneca vaccine candidate AZD1222 (also known as Covishield) has shown the lowest efficacy results of 60-70 per cent. Pune-based Serum Institute of India (SII) is conducting phase-3 trials on 1,600 Indian volunteers, with people in the know indicating that these trials are being done with two full doses. So far, they added, trials have shown efficacy of 60-70 per cent. If the primer-booster regimen (half dose followed by a full dose) has to be adopted, SII would need to conduct additional tests. Read on.